CrossBridge Bio Acquired by Eli Lilly and Co. for up to $300 Million
Cooley advised CrossBridge Bio, a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs), on its agreement to be acquired by Eli Lilly and Company (“Lilly”) for up to $300 million in cash, inclusive of an upfront payment and a subsequent payment upon achieving a specified development […]
GreenSpark and ReMatter Combine to Form ReSpark
Cooley advised GreenSpark Software, a cloud-native, AI-first platform for the metal recycling industry, on its combination with ReMatter, creating a single company known as ReSpark. The combined entity brings together two of the most advanced purpose-built software platforms in the metal recycling and scrap yard industry, unifying their products, teams and […]
Neurocrine Acquisition of Soleno for $2.9 Billion
Cooley advised Neurocrine, a leading biopharmaceutical company, on its agreement to acquire Soleno, a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases, for $2.9 billion. Neurocrine Acquisition of Soleno for $2.9 Billion
Korsana Biosciences Announces Merger With Cyclerion Therapeutics, Concurrent $380 Million Private Financing
Cooley advised the placement agents to Korsana Biosciences, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, in connection with an approximately $380 million private placement concurrent with its merger with Cyclerion Therapeutics. The syndicate of investors is led by Fairmount and Venrock Healthcare Capital […]
Pro Football Focus Sale of Enterprise Business to Teamworks
Cooley advised Pro Football Focus (PFF) on the sale of its enterprise business, including its proprietary game event data and analytics platform that NFL teams and collegiate football programs rely on daily, to Teamworks, the Operating System for Sports™ powering more than 7,000 elite sports organizations globally. Pro Football Focus […]
Kezar Life Sciences Acquired by Aurinia Pharmaceuticals
Cooley advised Kezar Life Sciences, a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, on its agreement to be acquired by Aurinia Pharmaceuticals, a biopharmaceutical company focused on developing therapies to people living with autoimmune diseases with high unmet medical needs, for $6.955 in […]
TheGuarantors Announces Growth Investment From Warburg Pincus
Cooley advised TheGuarantors, a leader in residential lease guarantee solutions and artificial intelligence-powered underwriting for the rental housing market, on a majority investment from Warburg Pincus, a pioneer of global growth investing. The investment will allow the company to scale, broaden access to housing for millions of renters and continue […]
Candid Therapeutics Announces Merger With Rallybio Corporation, Concurrent Private Financing of $505+ Million
Cooley advised Candid Therapeutics (Candid), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases, on its definitive merger agreement with Rallybio Corporation (Nasdaq: RLYB). Upon completion of the merger, the combined company expects to operate under the name Candid Therapeutics, Inc. and trade […]
35Pharma Enters Agreement to Be Acquired by GSK
Cooley advised 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company that specializes in developing novel protein-based therapeutics, on its agreement to sell to GSK, a global biopharma company, for $950 million. 35Pharma Enters Agreement to Be Acquired by GSK
IQM Announces Merger With Real Asset Acquisition Corp., Concurrent PIPE Financing
Cooley advised IQM Finland, a global leader in full-stack superconducting quantum computers, on its definitive business combination agreement with Real Asset Acquisition Corp. (Nasdaq: RAAQ, RAAQ), a special purpose acquisition company, which will result in IQM becoming a public company and listing American depositary shares on one of the two […]